- Orion’s first-quarter earnings per share (EPS) exceeded expectations at €0.44, compared to the estimated €0.40.
- Net sales for the quarter reached €354.6 million, surpassing the estimated €341 million.
- Earnings before interest and taxes (EBIT) amounted to €77.9 million.
- Following the announcement, Orion’s share price increased by 3.2%, reaching €49.08.
- A total of 74,933 Orion shares were traded.
- Current analyst recommendations include 2 buy ratings, 3 hold ratings, and 3 sell ratings.
“`
A look at Orion Oyj Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Orion Oyj, a company that develops pharmaceuticals and diagnostic kits, is showing a promising long-term outlook based on the Smartkarma Smart Scores. With a Growth score of 4 and a Resilience score of 4, the company seems well-positioned for expansion and able to withstand market challenges. Additionally, Orion Oyj has scored a high Momentum rating of 5, indicating strong market momentum that may propel the company towards achieving its strategic goals.
While the Value score may be on the lower side at 2, suggesting that the stock may not be undervalued compared to its peers, the Dividend score of 3 indicates a moderate level of dividend attractiveness. Overall, with favorable scores in Growth, Resilience, and Momentum, Orion Oyj appears to have a solid foundation for growth and sustainability, making it potentially attractive for long-term investors seeking growth opportunities in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
